{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T23:44:20Z","timestamp":1765583060956,"version":"3.48.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.apsb.2025.11.018","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T23:40:14Z","timestamp":1765582814000},"page":"6741-6742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New leap of BRD9 inhibitor: Imidazole substituents making BRD9 inhibitors excellent drug candidates for AML"],"prefix":"10.1016","volume":"15","author":[{"given":"Edward","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.11.018_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nrm.2017.26","article-title":"Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes","volume":"18","author":"Clapier","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2025.11.018_bib2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.molcel.2020.09.024","article-title":"Cancer-associated gain-of-function mutations activate a SWI\/SNF-family regulatory hub","volume":"80","author":"Clapier","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2025.11.018_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.11.018_bib4","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.str.2015.08.004","article-title":"A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications","volume":"23","author":"Flynn","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2025.11.018_bib5","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1038\/s41467-023-44081-6","article-title":"BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.11.018_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-022-00704-7","article-title":"BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma","volume":"12","author":"Weisberg","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.apsb.2025.11.018_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41419-019-1570-9","article-title":"BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition","volume":"10","author":"Del Gaudio","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.11.018_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nchembio.2115","article-title":"Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition","volume":"12","author":"Hohmann","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2025.11.018_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/ph17030392","article-title":"Identification and development of BRD9 chemical probes","volume":"17","author":"Colarusso","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.apsb.2025.11.018_bib10","doi-asserted-by":"crossref","first-page":"11326","DOI":"10.1021\/acs.jmedchem.4c00883","article-title":"Discovery of a highly potent and selective BRD9 PROTAC degrader based on E3 binder investigation for the treatment of hematological tumors","volume":"67","author":"Duan","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.11.018_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1078-0432.CCR-24-2583","article-title":"A phase I study of FHD-609, a heterobifunctional degrader of bromodomain-containing protein 9, in patients with advanced synovial sarcoma or SMARCB1-deficient tumors","volume":"31","author":"Livingston","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.11.018_bib12","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1016\/j.apsb.2025.08.006","article-title":"Key imidazolyl groups that induce phenylalanine flipping enhance the efficacy of oral BRD9 inhibitors for AML treatment","volume":"15","author":"Chen","year":"2025","journal-title":"Acta Pharm Sin B"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525007646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525007646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T23:42:15Z","timestamp":1765582935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525007646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2211383525007646"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.11.018","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New leap of BRD9 inhibitor: Imidazole substituents making BRD9 inhibitors excellent drug candidates for AML","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}